In3Bio is an innovation driven biotech company with a broad R&D platform of novel therapeutics that offer potential treatment for multiple cancers
In3Bio is a privately held biotechnology company based in the UK. Established in 2010, In3Bio’s innovation-driven program is dedicated to new therapeutics that can provide cancer patients new and effective treatments with emphasis on tolerability.
We have built a broad R&D platform that offer potential treatment for multiple indications of cancer, both as mono therapy and in combination with other treatments.
Create or design (something that has not existed before) ; be the originator of
Devote one’s time, effort and energy to a particular undertaking with the expectation of a worthwhile result
Make changes in something established, especially by introducing new methods, ideas, or products
We are committed to therapeutic improvement in the area of immuno-oncology, with a dedicated effort to invent, invest and innovate.
In3Bio’s diversified novel therapeutics are projected to enter into the clinic in 2020.
Programme under phase 1
Pipeline in CMO
Pipeline in advance development
Cancer target and more
Targeted drugs tested in combination with our pipelines
We primarily focus on pathway target immunisation (PTI), by stimulating the patient’s immune system to fight cancer. Using our immunisation approach, we have been able to develop new therapeutic options that are effective and tolerable in combination with existing treatments.
In3Bio has established collaborations with several leading academic institutions in Europe and works with Key Opinion Leaders. Our new therapeutics are without the heavy toxicity associated with standard treatment. This situates us in a competitive edge, allowing to provide a robust and versatile product pipeline.